N/A N=160 Randomized Prevention

Twitter-enabled Mobile Messaging for Smoking Relapse Prevention

Smoking

Bottom Line

View on ClinicalTrials.gov: NCT01602536 ↗

Enrolled (actual)

160

Serious AEs

0.0%

Results posted

Oct 2024

Primary outcome: Primary: Self-reported 7-day Point Prevalence Abstinence From Smoking That Was Sustained at 60 Days After the Quit Date — 26; 14 Participants

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: smoking cessation aides (Behavioral); Twitter (Behavioral)
Age: Adult · 18+ yrs
Sex: All
Sponsor: University of California, Irvine
Primary completion: Jun 2014

Outcome Measures

Outcome	Result	p-value
PRIMARY Self-reported 7-day Point Prevalence Abstinence From Smoking That Was Sustained at 60 Days After the Quit Date	26; 14	—
SECONDARY Level of Engagement Based on Tweet Volume	58.86; 0	—

Summary

We conducted a two-arm (test vs. control, N=160) randomized controlled trial of small, private, online support groups for quitting smoking with 20 people per group who were seeking to quit smoking. A novel feature was a bot (auto-messenger) that posted a daily cessation-related discussion topic in each group, timed to the group's quit date.

Eligibility Criteria

Inclusion Criteria

must have smoked 100 cigarettes during their lifetime
must currently smoke 5 or more cigarettes a day
must be in the preparation stage of quitting smoking
ages 18-59 years
English speaking
have a mobile phone with an unlimited texting plan and internet access
use text messaging at least once a week
use Facebook daily
have an active email account
live in the continental USA

Exclusion Criteria

a medical condition that is contra-indicated for nicotine replacement therapy:
pregnant
breast feeding
a recent heart attack
an irregular heartbeat
high blood pressure not controlled with medication
skin allergies to adhesive tape or serious skin problems
taking a prescription medicine for depression or anxiety
use drugs or marijuana regularly
live in the same household with another participant

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01602536). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.